Trade Mark Journal No.2026/031 31 July 2026

WO0000001928240 (5,42)

Office of origin: United States of America

Date of International Registration:22 May 2026
Date of designation in the UK: 22 May 2026
Image for mark 1928240

The mark consists of The mark consists of an abstract design of overlapping shapes curving to the left, each coming to a point with white space in between, the shape on the left is shaded with different shades of purple, extending downward from its outermost rounded edge is a rectangle shaded with gradients of purple, magenta, orange, gold and yellow, with dark purple forming a rounded triangle in the center, the rectangle's corner forms the lowest point of the design, the shape on the right extends upward from behind the rectangle and is gradient from purple to gold to yellow.

The mark contains the colours purple, magenta, orange, gold, yellow which are claimed as a feature of the mark.

The mark consists of The mark consists of an abstract design of overlapping shapes curving to the left, each coming to a point with white space in between, the shape on the left is shaded with different shades of purple, extending downward from its outermost rounded edge is a rectangle shaded with gradients of purple, magenta, orange, gold and yellow, with dark purple forming a rounded triangle in the center, the rectangle's corner forms the lowest point of the design, the shape on the right extends upward from behind the rectangle and is gradient from purple to gold to yellow.

International priority date claimed: 18 May 2026 (United States of America) (99830490)
Class 5
Pharmaceutical products.
Class 42
Pharmaceutical research and development.

Exelixis, Inc.

Representative: Anessa Kramer Honigman LLP, 39400 Woodward Avenue, Suite 101, Bloomfield Hills MI 48304-5151, UNITED STATES OF AMERICA